Yang Zhao, Qi Jingshu, Ping Dabing, Sun Xin, Tao Yanyan, Liu Chenghai, Peng Yuan
Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, China.
Front Pharmacol. 2022 Sep 20;13:999604. doi: 10.3389/fphar.2022.999604. eCollection 2022.
Organ fibrosis is a common pathological change that finally results in organ failure, which involves the destruction of parenchyma cells, the activation of mesenchymal cells and the imbalance of immunological cells. In recent years, although some breakthroughs have been made in understanding the pathogenesis and therapeutics of organ fibrosis, no registered drugs could directly target the fibrotic process, which constitutes a major biomedical challenge. (SM) is a well-known medicinal plant in China, which has been widely applied because of its pharmacological effects on anti-oxidative, anti-myocardial infarction, anti-fibrotic, anti-inflammatory, and anti-neoplastic properties. Accumulated evidence suggested that SM played critical roles against organ fibrosis and experiments by its multiple biological compounds. In this review, we discussed the recent advances on the phytochemistry and pharmacological mechanisms of SM and its active ingredients in liver, lung, kidney, and heart fibrosis, which might help to promote the treatment of fibrotic diseases in thorax and abdomainal viscera in clinic.
器官纤维化是一种常见的病理变化，最终会导致器官衰竭，它涉及实质细胞的破坏、间充质细胞的激活以及免疫细胞的失衡。近年来，尽管在理解器官纤维化的发病机制和治疗方法方面取得了一些突破，但尚无已注册的药物能够直接针对纤维化过程，这构成了一项重大的生物医学挑战。丹参（SM）是中国一种著名的药用植物，因其具有抗氧化、抗心肌梗死、抗纤维化、抗炎和抗肿瘤等药理作用而被广泛应用。越来越多的证据表明，丹参通过其多种生物活性化合物对器官纤维化起到关键作用。在这篇综述中，我们讨论了丹参及其活性成分在肝、肺、肾和心脏纤维化方面的植物化学和药理机制的最新进展，这可能有助于促进临床上胸腹部脏器纤维化疾病的治疗。
